title: Defining the structural determinants and a potential mechanism for inhibition of myosin phosphatase by the protein kinase C-potentiated inhibitor protein of 17 kDa.
abstract: Contractility of smooth muscle and non-muscle microfilaments involves phosphorylation of myosin II light chain. Myosin light chain phosphatase (MLCP) is specifically inhibited by the protein kinase C-potentiated inhibitor protein of 17 kDa, called CPI-17, as part of Ca(2+) sensitization of vascular smooth muscle contraction. Phosphorylation of Thr(38) in CPI-17 enhances inhibitory potency toward MLCP over 1000-fold. In this study we mapped regions of CPI-17 required for inhibition and investigated the mechanism using deletion and point mutants. Deletion of either the N-terminal 34 residues or C-terminal 27 residues gave no change in the IC(50) of either phospho- or unphospho-CPI-17. However, further deletion to give CPI-17 proteins of 1-102, 1-89, 1-76, and 1-67, resulted in much higher IC(50) values. The results indicate there is a minimal inhibitory domain between residues 35 and 120. A single Ala substitution at Tyr(41) eliminated phosphorylation-dependent inhibition, and phospho-Thr(38) in the Y41A protein was efficiently dephosphorylated by MLCP itself. The wild type CPI-17 expressed in fibroblast-induced bundling and contraction of actomyosin filaments, whereas expression of the Y41A protein had no obvious effects. Thus, a central domain of CPI-17(35-120) including phospho-Thr(38) is necessary for recognition by myosin phosphatase and Tyr(41) arrests dephosphorylation, thereby producing inhibition.
authors.affiliation: Division of Chemistry, Hokkaido University Graduate School of Science, Hokkaido 060-0810, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: S
authors.initials: S
authors.lastname: Senba
authors.forename: M
authors.initials: M
authors.lastname: Yazawa
authors.forename: D L
authors.initials: DL
authors.lastname: Brautigan
authors.forename: M
authors.initials: M
authors.lastname: Eto
mesh_terms: D008841:Actin Cytoskeleton / Q000187:drug effects; D000818:Animals; D001665:Binding Sites; D004305:Dose-Response Relationship, Drug; D009124:Muscle Proteins / Q000737:chemistry / Q000494:pharmacology*; D009131:Muscle, Smooth, Vascular; D009154:Mutation; D043263:Myosin-Light-Chain Phosphatase; D010749:Phosphoprotein Phosphatases / Q000037:antagonists & inhibitors*; D010750:Phosphoproteins / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017384:Sequence Deletion; D015398:Signal Transduction; D013552:Swine
chemical_list: D009124:Muscle Proteins; D010750:Phosphoproteins; C491519:Ppp1r14a protein, rat; D010749:Phosphoprotein Phosphatases; D043263:Myosin-Light-Chain Phosphatase